CPI-613 (Devimistat): Mechanism of Action

CPI-613 (Devimistat) MOA:Targeting PDH/TCA Cycle for Pancreatic Adenocarcinoma

🎯 check CPI-613 (Devimistat) product page

CPI-613 (Devimistat) is a high-affinity OGDH, PDH, and DLD inhibitor. It affects TCA cycle and AMPK signaling by disrupting mitochondrial energy metabolism and increasing ROS production, effectively inhibiting tumor cell proliferation and inducing apoptosis.

Primary Applications and Mechanism of Action